Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Soliqua (lixisenatide/insulin glargine)
pCPA File Number:
21088
Negotiation Status:
Concluded with an LOI
Indication(s):
Diabetes Mellitus, Type 2
Sponsor/Manufacturer:
Sanofi-aventis Canada Inc.
CADTH Project Number:
SR0564-000
pCPA Engagement Letter Issued:
2019-04-16
Negotiation Process Concluded:
2019-11-21